A Virus That Kills 40-75% of Its Victims Just Resurfaced. We've Known About It for 28 Years.

COVID killed about 1% of the people it infected. Nipah kills 40-75%.

India just confirmed another outbreak in West Bengal. Third time in that state since 2001. Kerala—the world's highest-risk region—had its last outbreak seven months ago. Three cases, two deaths.

This is the 12th outbreak since 1998.

We still don't have a vaccine.

The Virus That Keeps Knocking

Nipah doesn't spread like COVID. It can't jump easily from person to person. Most outbreaks stay small—under 20 cases.

But when it hits, it's brutal.

The first outbreak in Malaysia in 1998 infected 265 people. 108 died. Some outbreaks in Bangladesh have pushed fatality rates above 90%.

And it keeps coming back. Nearly annual outbreaks since 1998, all in the same bat-to-human corridor across South and Southeast Asia.

Here's the pattern: fruit bats (Pteropus genus, also called flying foxes) carry the virus without getting sick. They're the natural reservoir. Humans catch it through contaminated food (especially date palm sap), contact with sick animals, or occasionally person-to-person.

Kerala's dense populations of Indian flying foxes overlap with farms, villages, date palm groves. Same geography, same bats, same risk. Every few years, the virus spills over again.

Climate Changed the Map

The bat-human overlap zone is widening.

Deforestation and agricultural expansion destroy bat habitat. Bats lose their forests and move to farms looking for food. Climate change is making it worse—shifting bat ranges into new territories.

Researchers tracking Pteropus populations warn that warming temperatures could expand their range across Asia, bringing Nipah into areas that've never seen it.

The original 1998 Malaysia outbreak? Linked to deforestation for pulpwood and industrial plantations. El Niño-driven drought pushed bats into pig farms. That's how it started.

Now we're doing the same thing at scale. Forests shrinking, temperatures rising, bats adapting. The spillover risk grows.

28 Years, No Vaccine

Here's the uncomfortable part.

WHO identified Nipah as a priority pathogen for its R&D Blueprint. It's been on the pandemic watch list for years.

Oxford University just launched the world's first Phase II vaccine trial in Bangladesh. Led by Sarah Gilbert, who helped develop the AstraZeneca COVID vaccine. Funded by CEPI (Coalition for Epidemic Preparedness Innovations).

That's progress. Real progress.

But it's 2026. The virus was discovered in 1998. We've had 28 years.

Why no vaccine yet?

Because Nipah kills 20-30 people per outbreak. Sometimes fewer. Sometimes more, but never enough to justify massive pharma investment. The market's too small. The outbreaks are sporadic. There's no sustained funding pipeline.

It's not that we can't make a Nipah vaccine. It's that we haven't prioritized it.

COVID changed that calculation—a little. Pandemic preparedness funding surged. Technologies developed for COVID (mRNA platforms, rapid trials) are being repurposed. The Oxford trial is happening now partly because of that infrastructure.

But funding's already drying up. The US just cut $12 billion in pandemic surveillance as bird flu (H5N1) circles. Nipah's back on the "we'll deal with it when it becomes urgent" list.

One Mutation Away

The nightmare scenario isn't the current virus. It's the mutation.

Right now, Nipah doesn't spread efficiently between humans. Most transmission is bat-to-human or through contaminated food. Person-to-person happens, but it's not easy.

One genetic change could flip that.

If Nipah evolves efficient human-to-human transmission while keeping its 40-75% fatality rate, we're looking at a pathogen that makes COVID look gentle.

We got lucky with COVID—deadly enough to take seriously, mild enough that most people survived. Nipah's the opposite: terrifying fatality rate, limited spread.

But biology doesn't care about our preferences. The virus is replicating, adapting, testing the boundaries of transmission every time it jumps to a human host.

And we're expanding the testing ground. More deforestation, more climate disruption, more bat-human contact. More chances for the virus to find a mutation that works.

The Math We're Ignoring

Here's what we know:

• Nipah kills 40-75% of infected people
• It resurfaces nearly every year in the same regions
• Climate change is widening the bat habitat overlap with humans
• We've had 28 years to develop a vaccine
• We're in Phase II trials now, which means a licensed vaccine is still years away

The current outbreak in West Bengal will likely stay contained. India's gotten good at Nipah response—contact tracing, isolation, surveillance. Kerala's built a whole infrastructure around it.

But containment isn't prevention. And prevention requires either destroying bat habitat entirely (ecological disaster) or vaccinating populations at risk (which we can't do yet).

So we wait. And every year, Nipah knocks again.

The question isn't whether the next outbreak will happen. It's whether we'll have a vaccine ready before the virus evolves into something we can't contain.

Right now, we're betting on luck.